Is ALLR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% BioAtla N/A N/A -271.17%

Is ATOS or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% BioAtla N/A N/A -271.17%

Is BCAB or NEUP more profitable?

BioAtla's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -271.17% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts rate BCAB or ALVR?

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 6,372.49%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, BCAB or ALVR?

BioAtla has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $8.50M 0.60 -$59.61M -$25.45 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BCAB or ALVR more profitable?

BioAtla's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -271.17% AlloVir N/A -71.03% -61.27%

Is CELU or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% BioAtla N/A N/A -271.17%

BioAtla (BCAB) Competitors

$3.09 -0.36 (-10.43%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.10 +0.01 (+0.16%)

As of 08/14/2026 07:34 PM Eastern

Compare

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

Should you buy BioAtla stock or one of its competitors? BioAtla's main competitors and comparable companies include Allarity Therapeutics (ALLR), Atossa Genetics (ATOS), Neuphoria Therapeutics (NEUP), AlloVir (ALVR), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioAtla compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 648.18%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 6,372.49%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
BioAtla	N/A	N/A	-271.17%

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Allarity Therapeutics has higher earnings, but lower revenue than BioAtla. Allarity Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	68.11	-$11.23M	-$0.72	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

In the previous week, Allarity Therapeutics had 3 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for Allarity Therapeutics and 2 mentions for BioAtla. BioAtla's average media sentiment score of 2.44 beat Allarity Therapeutics' score of 0.97 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
BioAtla	Very Positive

Allarity Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

BioAtla beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Atossa Genetics has higher earnings, but lower revenue than BioAtla. Atossa Genetics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

Atossa Genetics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

BioAtla's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
BioAtla	N/A	N/A	-271.17%

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 682.05%. BioAtla has a consensus price target of $200.00, indicating a potential upside of 6,372.49%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. BioAtla's average media sentiment score of 2.44 beat Atossa Genetics' score of 0.93 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Positive
BioAtla	Very Positive

Summary

Atossa Genetics beats BioAtla on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to Neuphoria Therapeutics?

BioAtla (NASDAQ:BCAB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

BioAtla has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 2 mentions for BioAtla. BioAtla's average media sentiment score of 2.44 beat Neuphoria Therapeutics' score of 0.37 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Neuphoria Therapeutics	Neutral

Neuphoria Therapeutics has higher revenue and earnings than BioAtla. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A
Neuphoria Therapeutics	$15.65M	1.34	-$370K	-$11.06	N/A

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 6,372.49%. Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 442.64%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.2% of BioAtla shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-271.17%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Summary

BioAtla beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to AlloVir?

BioAtla (NASDAQ:BCAB) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

BioAtla's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-271.17%
AlloVir	N/A	-71.03%	-61.27%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioAtla has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, BioAtla had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for BioAtla and 0 mentions for AlloVir. BioAtla's average media sentiment score of 2.44 beat AlloVir's score of 0.00 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
AlloVir	Neutral

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 6,372.49%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioAtla has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

BioAtla beats AlloVir on 11 of the 14 factors compared between the two stocks.

How does BioAtla compare to Celularity?

Celularity (NASDAQ:CELU) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Celularity presently has a consensus target price of $6.00, suggesting a potential upside of 762.32%. BioAtla has a consensus target price of $200.00, suggesting a potential upside of 6,372.49%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.76	-$91.72M	-$3.33	N/A
BioAtla	$8.50M	0.60	-$59.61M	-$25.45	N/A

In the previous week, BioAtla had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Celularity. BioAtla's average media sentiment score of 2.44 beat Celularity's score of 1.89 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Very Positive
BioAtla	Very Positive

19.0% of Celularity shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Celularity has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

BioAtla has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
BioAtla	N/A	N/A	-271.17%

Summary

BioAtla beats Celularity on 8 of the 13 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.12M	$3.72B	$7.02B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.12	10.72	270.72	25.33
Price / Sales	0.60	1,233.84	574.35	73.89
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-0.11	16.78	12.92	6.25
Net Income	-$59.61M	-$13.32M	$3.45B	$347.82M
7 Day Performance	-10.69%	1.75%	1.15%	1.08%
1 Month Performance	-27.46%	1.13%	1.37%	0.82%
1 Year Performance	-83.19%	54.35%	62.52%	20.99%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	2.2629 of 5 stars	$3.09 -10.4%	$200.00 +6,372.5%	-83.0%	$5.12M	$8.50M	N/A	60	Positive News Earnings Report High Trading Volume
ALLR Allarity Therapeutics	2.7057 of 5 stars	$1.41 -0.1%	$10.25 +627.5%	+39.8%	$22.42M	$320K	N/A	10	News Coverage Earnings Report Gap Up
ATOS Atossa Genetics	2.6175 of 5 stars	$2.42 +1.9%	$20.33 +742.0%	-77.8%	$20.80M	N/A	N/A	8	News Coverage Earnings Report Analyst Upgrade
NEUP Neuphoria Therapeutics	2.3809 of 5 stars	$3.83 -0.8%	$21.00 +448.3%	-52.2%	$20.68M	$15.65M	N/A	N/A	Short Interest Increase
ALVR AlloVir	N/A	$4.07 -2.9%	N/A	+70.2%	$20.53M	N/A	N/A	110	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

How does BioAtla compare to Allarity Therapeutics?

Summary

How does BioAtla compare to Atossa Genetics?

Summary

How does BioAtla compare to Neuphoria Therapeutics?

Summary

How does BioAtla compare to AlloVir?

Summary

How does BioAtla compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. ALLR, ATOS, NEUP, ALVR, and CELU

How does BioAtla compare to Allarity Therapeutics?

Do analysts recommend ALLR or BCAB?

Is ALLR or BCAB more profitable?

Do institutionals and insiders have more ownership in ALLR or BCAB?

Which has stronger earnings and valuation, ALLR or BCAB?

Does the media favor ALLR or BCAB?

Which has more risk and volatility, ALLR or BCAB?

Summary

How does BioAtla compare to Atossa Genetics?

Do institutionals & insiders have more ownership in ATOS or BCAB?

Which has better valuation and earnings, ATOS or BCAB?

Which has more risk & volatility, ATOS or BCAB?

Is ATOS or BCAB more profitable?

Do analysts prefer ATOS or BCAB?

Does the media favor ATOS or BCAB?

Summary

How does BioAtla compare to Neuphoria Therapeutics?

Which has more volatility & risk, BCAB or NEUP?

Does the media prefer BCAB or NEUP?

Which has stronger valuation & earnings, BCAB or NEUP?

Do analysts prefer BCAB or NEUP?

Do insiders & institutionals hold more shares of BCAB or NEUP?

Is BCAB or NEUP more profitable?

Summary

How does BioAtla compare to AlloVir?

Is BCAB or ALVR more profitable?

Do insiders and institutionals have more ownership in BCAB or ALVR?

Which has more risk & volatility, BCAB or ALVR?

Does the media prefer BCAB or ALVR?

Do analysts rate BCAB or ALVR?

Which has stronger earnings & valuation, BCAB or ALVR?

Summary

How does BioAtla compare to Celularity?

Do analysts recommend CELU or BCAB?

Which has preferable earnings and valuation, CELU or BCAB?

Does the media favor CELU or BCAB?

Do institutionals & insiders hold more shares of CELU or BCAB?

Which has more volatility & risk, CELU or BCAB?

Is CELU or BCAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools